appear to show a cross-sensitivity to the drugs listed in Table 3 , but in the case of favism the situation is somewhat different (Szeinberg et al. 1957) . American negroes are apparently insensitive to the fava bean and in S. Caucasians favism is not apparently seen in all individuals who are enzyme deficient. It seems as if an abnormal gene closely linked to the G6PD one may also be concerned and results in the abnormal metabolism of bean products.
The detection of G6PD deficiency is not difficult. The enzyme can easily be assayed directly by -measuring the oxidation of TPNH spectrophotometrically in a red cell system containing the requisite substrates (Prankerd 1963) . Alternatively the stability of reduced glutathione against oxidation in the presence of acetylphenylhydrazine can be measured (Beutler et al. 1957 ), but this is not a particularly sensitive test. In the absence of suitable equipment and in field studies two simple methods, one involving the reduction of methaemoglobin (Brewer et al. 1960 ) and the other the reduction and decoloration of brilliant cresyl blue (Prankerd 1963) , can be used.
Several variants of G6PD deficiency may be seen clinically. In one of the commonest, that producing drug sensitivity in Negroes, only 10-15% of the enzyme is present in the red cells. In S. Caucasians the deficiency is greater and only 0-5% of enzyme is present. These subjects are often sensitive to the fava bean and in many of them a haemolytic state in the newborn is also a feature. In N. Caucasians a total deficiency of enzyme is occasionally seen and is associated with a s v re nonspherocytic hemolytic disease dating fr,m birth. One such patient had red cells which appeared to be insensitive to primaquine when his cells wer9 transfused to a normal donor taking this drug (Bowdler & Prankerd 1964) .
Chemical studies of the enzyme in deficient subjects are still in an early stage. The enzyme seems to be normal in character in Negroes but deficient in quantity. Although I have so far discussed enzyme proteins as if there were only one, electrophoretic studies demonstrate the existence of two isoenzymes in the red cells of normal subjects. In N. Caucasians with hereditary nonspherocytic hemolytic anxmia one of these proteins appears to be chemically abnormal, but it is very difficult to obtain sufficient enzyme for study (Kirkman & Crowell 1963) .
Other differences between G6PD variants also exist; for instance tissue cells other than the red cell, such as leucocytes and liver cells, share the deficiency in S. Caucasians, but not in Negroes. In our patient with nonspherocytic haemolytic disease leucocyte enzymes were normal in activity.
The prevalence of this harmful genetic abnormality in many communities has led people to wonder how the gene frequency is maintained. Following the analogy of sickle cell disease and its protective effect against malaria the relationship of this defect to malarial infestation has been investigated and it appears that there is also a degree of protection afforded by a deficiency of G6PD. (Allison & Clyde 1961) . The mechanism of this could be a result of the instability of reduced glutathione in the red cells because this compound is required for the growth of malarial parasites. Lect 
Acetylation Polymorphisms
The administration of a standardized dose of a drug in exactly the same way to a large number of healthy human beings allows one to construct a frequency distribution histogram of the effect produced by the drug or some feature of its metabolism in the body. The finding of a bimodal or trimodal distribution curve can lead to knowledge of a new genetic polymorphism (Evans 1962) .
Polymorphic Acetylation
The acetylation polymorphism was found by studying the metabolism of isoniazid (Fig 1) in human populations. The frequency distribution histogram of plasma isoniazid concentrations determined six hours after the oral administration of 10 mg of isoniazid per kg of body weight yields a bimodal pattern. When this test was performed in 267 members of 53 two-generation Caucasian families, genetic analysis revealed that slow inactivation of the compound is an autosomal mendelian recessive character (Evans, Manley & McKusick 1960) . The data also showed that there is a 'dosage effect' for the gene controlling the dominant character.
The fall of plasma isoniazid concentration with time is exponential following oral dosage (Evans, Storey, Wittstadt & Manley 1960) . The same is true of the fall in isoniazid concentration when the drug has been administered by intravenous injection (Jenne 1960) . This suggests that the intestine is not responsible for the difference between the two phenotypes. Similarly the clearance of isoniazid through the kidney and calculated tubular reabsorption is the same in both phenotypes (Jenne et al. 1961 ). These facts strongly suggested that a metabolic factor accounted for the different speeds of inactivation of the drug in the two -genetically determined phenotypes.
The studies of Hughes et al. (1954) and Hughes et al. (1955) revealed: (1) That all the isoniazid swallowed in an oral dose could be accounted for in one form or another in the urine. (2) That the pattern of the various metabolites in an individual remained constant even when he was given isoniazid continuously over a period of weeks.
(3) In a population of individuals there was an inverse relationship between the percentage of a dose of isoniazid excreted as the free compound and the percentage excreted as acetyl isoniazid. For these reasons it was considered possible that acetylation could be responsible for the difference between the two phenotypes. Therefore 58 fasting volunteer medical students were given a dose of 160 mg of sulphamethazine per kg metabolically active mass (weight to the power of 0 7, ) and the urine collected for eight hours afterwards. The percentage of the drug acetylated was determined in the urine and its frequency distribution was bimodal. Seventeen of these subjects were phenotyped by means of isoniazid: 6 rapid inactivators were found to lie in the mode of extensive acetylators of sulphamethazine; and 11 slow inactivators of isoniazid were amongst the group of less extensive acetylators of sulphamethazine. This corroborated the suspicion that the genetic polymorphism depended upon acetylation (Evans 1962) .
In vitro studies using small pieces of healthy (Evans & White 1964) . This shows that the enzyme responsible for the polymorphism is an acetyl transferase. The most important clinical implications of these findings concern the occurrence of polyneuropathy in tuberculous patients treated with isoniazid. The study of Devadatta et al. (1960) revealed that slow inactivators are much more prone to develop this complication than are rapid inactivators of the drug (see Evans & Clarke 1961 ). Hydrallazine (Fig 1) possesses a mono-substituted hydrazine side chain as does isoniazid. This grouping is electronegative and a good potential acceptor of acetyl groups. The metabolism of hydrallazine has been investigated by an in vitro technique wherein human liver homogenates were prepared containing acetyl coenzyme A. The homogenates were then divided into two portions. To one portion was added sulphamethazine and to the other hydrallazine. The amount of sulphamethazine metabolized allowed the liver biopsy specimens to be phenotyped. Rapid acetylator livers metabolized significantly more hydrallazine than did slow acetylator livers. This result strongly suggests that the acetylation of hydrallazine is polymorphic (Evans & White 1964) . It raises the interesting speculation that the development of polyneuropathy and of a systemic lupus erythematosus-like syndrome may occur more frequently in slow acetylator subjects. Phenelzine (Fig 1) also possesses a monosubstituted hydrazine side chain. In collaboration with Dr T C Pratt and Dr K Davison, a clinical study is being performed as follows:
Subjects judged to be typical endogenous -depressives are phenotyped with an isoniazid test. The result is withheld from the psychiatric observers who proceed to treat the patient with phenelzine and note the response of mood and incidence of side-efltects. Interim results after the study of 30 patients show that the elevation of mood is much the same in both phenotypes. Severe side-effects were noted in 6 patients only. These were schizophrenia-like reactions. All 6 patients in whom they occurred were slow inactivators (Table 1 ). Here again it seems that the genetic constitution of an individual predisposes to the development of a toxic reaction to a drug. It is suggested that the elevation of mood was the same in both acetylator phenotypes because phenelzine is a powerful enzymic inhibitor, and that probably sufficient drug was available in both phenotypes to block the monoamine oxidase (and possibly other enzymes) (Fig 2) . The excess, however, may be eliminated more quickly in rapid acetylators, thus preventing the occurrence of severe side-effects in this phenotype.
Monomorphic Acetylation Three items of information suggest that paraaminosalicylic acid (PAS) is monomorphically acetylated in human populations: (1) The administration of a standardized dose of PAS to 100 volunteer subjects and determination of the percentage acetylated in the urine gave an unimodal curve (Evans 1963) . This is quite unlike the result obtained using sulphamethazine mentioned above.
(2) The half-life of plasma PAS concentrations following intravenous injection is the same in slow and rapid acetylator subjects (Jenne et al. 1961) . (3) Red cells lack the capacity to acetylate isoniazid but can acetylate PAS and paraaminobenzoic acid (PABA). Investigation of the latter property in 130 subjects yielded an unimodal distribution curve (Motulsky & Steinmann 1962). Peters (1964, personal communication) has shown that sulphanilamideisacetylated tothe same extent in slow and rapid acetylators of isoniazid.
Blondheim & Kunkel (1950) had reported that acetyl PABA can be found in 'caput meduswe' veins of cirrhotics following oral administration of the drug.
Paired biopsy specimens of healthy liver and healthy jejunal mucosa have recently been obtained from subjects undergoing gastrojejunostomy. Each specimen has been homogenized with acetyl CoA and the homogenate divided into two portions. Sulphamethazine was added to one portion and PABA to the other. The liver sulphamethazine results allow the subjects to be classified as slow and rapid acetylators. Preliminary results show jejunal mucosa to be very active in acetylating PABA and suggest that this property is monomorphically distributed (Evans &White,unpublished observations; Fig 3) .
Conclusions: It seems that the human body has polymorphic mechanisms to acetylate some drugs and monomorphic mechanisms to acetylate others. So far it has not been possible to ascertain the natural substrates for these mechanisms. An interesting sex-limited variation has been described in the capacity of rat kidneys to acetylate PABA in vitro. Acetyl para-amino hippurate is formed to a much greater extent by kidneys from male rats than by kidneys from female rats (Koivusalo & Luukkainen 1963) .
It is suggested that these findings have a bearing upon drug toxicity. Extrapolations of drug metabolism cannot be made from one species to another, neither can they be made from one member of the same species to another, nor from one organ of the same individual to another, without the occurrence of considerable diversity being recognized as a possibility.
These complexities should be borne in mind when investigating new drugs.
Professor C Rimington (Department ofChemicalPathology, University College Hospital Medical School, London) Drug and Enzyme Interactions in the Porphyrias When discussing drugs and enzymes in relation to the porphyrias, one is handicapped by ignorance of the precise biochemical lesions responsible for the increased excretion in urine or stool of the various porphyrins or porphyrin precursors which characterize them. It is helpful, nevertheless, to examine the clinical observations which show that certain drugs may affect these diseases and to attempt biochemical interpretations based upon such hypotheses as have been put forward.
Acute intermittent porphyria was first described by Stokvis in 1889, the case being that of a woman who had taken sulphonal. Her urine became dark red and she died. Sulphonal had been introduced as a hypnotic only in the previous year but within a short time several more cases were reported in which the taking of sulphonal was associated with unusual forms of nervous disturbance and the passing of urine rich in porphyrins. The drugs tetronal and trional had similar effects on certain individuals. At the same time reports were presented of the occurrence of a similar type of disease without any history of drug taking. We now know that whilst acute porphyria generally manifests itself as a series of abdominal and nervous attacks, it may also remain latent and symptomless in some affected individuals until it is provoked by some toxic insult. Barbiturates proved to be even more dangerous in this respect than the sulphonal drugs. Barbiturates were introduced into medicine in 1903 and again reports began to appear of severe illness following their prolonged administration to certain individuals. Porphyrinuria or porphobilinogenuria, paralyses and mental disturbance dominated the picture. Waldenstrom (1937) clearly recognized the association between barbiturates and the severity of nervous symptoms in acute porphyrics. This has been confirmed in a more recent study by Goldberg (1959) who compared in 48 patients the incidence of paralysis and their history of barbiturate administration (Fig 1) . He also showed in an experimental study upon rabbits that certain barbiturates and particularly those such as allobarbitone and quinalbarbitone, which contain allyl groups, are capable of causing increased excretion of urinary porphyrin (Goldberg 1954) . 
